JP2002528123A5 - - Google Patents

Download PDF

Info

Publication number
JP2002528123A5
JP2002528123A5 JP2000579757A JP2000579757A JP2002528123A5 JP 2002528123 A5 JP2002528123 A5 JP 2002528123A5 JP 2000579757 A JP2000579757 A JP 2000579757A JP 2000579757 A JP2000579757 A JP 2000579757A JP 2002528123 A5 JP2002528123 A5 JP 2002528123A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid sequence
antigen
sequence
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000579757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002528123A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/026291 external-priority patent/WO2000026385A1/en
Publication of JP2002528123A publication Critical patent/JP2002528123A/ja
Publication of JP2002528123A5 publication Critical patent/JP2002528123A5/ja
Pending legal-status Critical Current

Links

JP2000579757A 1998-11-05 1999-11-05 遺伝子免疫のための核酸構築物 Pending JP2002528123A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10716998P 1998-11-05 1998-11-05
US60/107,169 1998-11-05
PCT/US1999/026291 WO2000026385A1 (en) 1998-11-05 1999-11-05 Nucleic acid constructs for genetic immunization

Publications (2)

Publication Number Publication Date
JP2002528123A JP2002528123A (ja) 2002-09-03
JP2002528123A5 true JP2002528123A5 (https=) 2006-12-21

Family

ID=22315199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000579757A Pending JP2002528123A (ja) 1998-11-05 1999-11-05 遺伝子免疫のための核酸構築物

Country Status (13)

Country Link
EP (1) EP1119630B1 (https=)
JP (1) JP2002528123A (https=)
AT (1) ATE315658T1 (https=)
AU (1) AU775939B2 (https=)
CA (1) CA2349505A1 (https=)
CY (1) CY1105600T1 (https=)
DE (1) DE69929470T2 (https=)
DK (1) DK1119630T3 (https=)
ES (1) ES2257879T3 (https=)
IL (1) IL142980A0 (https=)
NZ (1) NZ512078A (https=)
PT (1) PT1119630E (https=)
WO (1) WO2000026385A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
ATE285806T1 (de) 1999-10-11 2005-01-15 Felton International Inc Universelle antiinfektionsschutzvorrichtung für nadellose injektoren
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
AU2001266163B2 (en) * 2000-06-22 2006-07-13 Celltech Pharmaceticals Limited Modification of hepatitis b core antigen
KR20030034194A (ko) * 2000-09-19 2003-05-01 트리펩 아베 병원체 내에서 수용체에 대한 항체를 재유도하는리간드/수용체 특이성 교환기
JP2004535799A (ja) * 2001-05-18 2004-12-02 パウダージェクト ワクチンズ,インコーポレーテッド ワクチン組成物
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
JP4791730B2 (ja) * 2002-09-27 2011-10-12 パウダージェクト リサーチ リミテッド 核酸コーティング粒子
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
EP2230249A3 (en) 2003-02-06 2010-12-22 ChronTech Pharma AB Antigen/antibody or ligand/receptor glycosylated specificity exchangers
AU2007306936B2 (en) 2006-10-12 2014-02-06 The University Of Queensland Compositions and methods for modulating immune responses
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptídeo de ch3 da ige.
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
WO2011027257A2 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US11311610B2 (en) 2010-11-01 2022-04-26 University Of Technology Sydney Immune-modulating agents and uses therefor
EA032364B1 (ru) 2011-02-11 2019-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine

Similar Documents

Publication Publication Date Title
JP2002528123A5 (https=)
Ulrich et al. Core particles of hepatitis B virus as carrier for foreign epitopes
Celis et al. Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen
EP1685251B1 (en) Nucleic acid constructs
JP2004527213A5 (https=)
CA2413546A1 (en) Modification of hepatitis b core antigen
JP2001512748A5 (https=)
CA2305683A1 (en) Immunogenic peptides from the hpv e7 protein
US6492145B1 (en) Vaccine against mycobacterial infections
JP2002517249A5 (https=)
Morgan et al. Comparative immunogenicity studies on Epstein‐Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton‐top tamarins
EP0913157B1 (en) A composite vaccine which contains antigen, antibody and recombinant dna and its preparing method
JP2004536107A5 (https=)
JP2002515249A5 (https=)
CN118286410B (zh) 一种偶联CD8抗体的肿瘤mRNA疫苗的制备方法
KR100686356B1 (ko) 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제
Sjolander et al. Bacterial Expression Systems Based on a Protein A and Protein G Designed for the Production of Immunogens: Applications to Plasmodium falciparum Malaria Antigens
AU700104B2 (en) Prolactin as a vaccine adjuvant
KR100905249B1 (ko) Dna와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션
Sanchez et al. Evidence for the presence of repeating antigenic determinants in the major and minor polypeptides derived from hepatitis B surface antigen
JP2021040627A5 (https=)
JP2001517447A (ja) B型肝炎ウイルスポリペプチド
Yong Kang et al. Expression of Hepatitis B Virus Surface Antigen Gene in Mammalian, Yeast, and Insect Cells
WO2025218651A1 (zh) 一种重组腺病毒载体疫苗制剂及其制备方法
EP1545594A1 (en) Bacteriophage-mediated immunisation against hepatitis